The potential of AI for healthcare is undeniable, with the technology fuelling a resurgence of venture capital flowing into medical software and healthcare technologyThe potential of AI for healthcare is undeniable, with the technology fuelling a resurgence of venture capital flowing into medical software and healthcare technology

The “unsexy” revolution within healthcare AI

4 min read

The potential of AI for healthcare is undeniable, with the technology fuelling a resurgence of venture capital flowing into medical software and healthcare technology. While initial AI implementations often focused on novel, standalone applications like ambient AI scribes, a quiet but significant shift is now underway.  

The real revolution is happening in the back office. AI tools that can streamline provider operations and revenue cycle management — the largest and most entrenched cost centers in the system — are drawing the most attention and funding. In the near future, AI governance tools that allow clinical AI to remain within the necessary guardrails will also become increasingly popular. 

These developments reflect the maturation of healthcare technology as it transitions from standalone applications to “unsexy” innovations in provider operations and workflows. These innovations offer targeted support to healthcare participants while avoiding hype cycles. 

An end to AI scribes 

Ambient AI scribes are Generative AI software tools that use speech recognition to listen in to patient-doctor conversations and automatically transcribe them. These applications can also generate structured clinical summaries and referral letters – helping to reduce the time doctors spend on documentation and manual data entry.  

While proving a useful tool, the market is over-saturated, numbering over 150 standalone AI scribe companies. By the end of 2026, this is likely to collapse into a feature set. The top two to three players which are able to distinguish themselves from their competitors and prove the most trustworthy and scalable, will be acquired by Electronic Health Record (EHR) incumbents like Epic and Oracle or large platforms such as Microsoft and Nuance. The rest will either die or pivot, as ​​ambient listening becomes a commodity feature of the Operating System, not a venture-backable standalone product.  

The ‘App for that’ era of healthtech is over, killed by the expiration of pandemic-era reimbursement waivers and a rigorous demand for return on investment (ROI) from payers and providers. In its place we will witness a shift toward provider operations and Agentic AI workflows in 2026, that replace the cognitive drudgery of administration and empower those on the frontlines of healthcare. 

The year of Agentic workflows 

2026 will be the year that Agentic AI becomes embedded into administrative workflows, with autonomous systems soon set to handle over half of prior authorisations, documentation tasks and claims processing.  

We will also witness the rise of AI Sentinels becoming an integral feature of workflows in the near future, as this technology becomes mandatory. These are intelligent surveillance systems which are incorporated into clinical AI, such as diagnostic software, to monitor for errors, hallucinations, or bias. This technology ensures that AI tools meet regulatory compliance with healthcare standards such as the General Data Protection Regulation (GDPR), the Health Insurance Portability and Accountability Act (HIPAA), and other data regulations.  

By 2026, regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) will likely require these for the deployment of AI tools in healthcare. This will generate a nascent but growing market for “governance as a service” in healthtech. 

The rise of vertical AI 

The convergence of Agentic AI and proprietary healthcare data will create highly specialized intelligence that can become a valuable business asset. Known as vertical intelligence, this type of AI is trained on sector-specific data, such as genomics or radiology metadata, enabling it to solve specific clinical problems. Examples include specialized AI systems that operate within a particular niche, such as AI radiology environments. 

Vertical AI will become much more valuable than its counterpart – horizontal AI, which is trained on less specific, broader datasets. Examples include general AI assistants that are applied across multiple workflows, rather than tackling a single task. The lack of accuracy makes horizontal AI tools much less efficient, and their broader implementation means they are harder to regulate and risk assess. 

Optimising AI for a pragmatic future 

In 2026, healthcare AI is entering a more pragmatic and consequential phase, moving decisively from flashy, standalone applications toward deeply integrated, operational tools that address the system’s most entrenched inefficiencies. 

The hype around AI scribes will have largely subsided, consolidating into a few scalable offerings, while the real value will emerge from Agentic AI workflows that autonomously handle administrative burdens and safeguard regulatory compliance. This signals a shift in the broader maturation of healthtech.  

Success will increasingly hinge not on novelty, but on measurable impact, trustworthiness, and integration into everyday clinical operations. Simultaneously, highly specialized vertical AI will surpass horizontal intelligence in both utility and business value, offering precise solutions to complex problems. These trends represent an “unsexy revolution” where AI is no longer a standalone spectacle, but an embedded, intelligent force that empowers healthcare professionals without replacing them. 

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Securities Fraud Investigation Into Corcept Therapeutics Incorporated (CORT) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Securities Fraud Investigation Into Corcept Therapeutics Incorporated (CORT) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation
Share
AI Journal2026/02/05 04:00
BlackRock boosts AI and US equity exposure in $185 billion models

BlackRock boosts AI and US equity exposure in $185 billion models

The post BlackRock boosts AI and US equity exposure in $185 billion models appeared on BitcoinEthereumNews.com. BlackRock is steering $185 billion worth of model portfolios deeper into US stocks and artificial intelligence. The decision came this week as the asset manager adjusted its entire model suite, increasing its equity allocation and dumping exposure to international developed markets. The firm now sits 2% overweight on stocks, after money moved between several of its biggest exchange-traded funds. This wasn’t a slow shuffle. Billions flowed across multiple ETFs on Tuesday as BlackRock executed the realignment. The iShares S&P 100 ETF (OEF) alone brought in $3.4 billion, the largest single-day haul in its history. The iShares Core S&P 500 ETF (IVV) collected $2.3 billion, while the iShares US Equity Factor Rotation Active ETF (DYNF) added nearly $2 billion. The rebalancing triggered swift inflows and outflows that realigned investor exposure on the back of performance data and macroeconomic outlooks. BlackRock raises equities on strong US earnings The model updates come as BlackRock backs the rally in American stocks, fueled by strong earnings and optimism around rate cuts. In an investment letter obtained by Bloomberg, the firm said US companies have delivered 11% earnings growth since the third quarter of 2024. Meanwhile, earnings across other developed markets barely touched 2%. That gap helped push the decision to drop international holdings in favor of American ones. Michael Gates, lead portfolio manager for BlackRock’s Target Allocation ETF model portfolio suite, said the US market is the only one showing consistency in sales growth, profit delivery, and revisions in analyst forecasts. “The US equity market continues to stand alone in terms of earnings delivery, sales growth and sustainable trends in analyst estimates and revisions,” Michael wrote. He added that non-US developed markets lagged far behind, especially when it came to sales. This week’s changes reflect that position. The move was made ahead of the Federal…
Share
BitcoinEthereumNews2025/09/18 01:44
Over 80% of 135 Ethereum L2s record below 1 user operation per second

Over 80% of 135 Ethereum L2s record below 1 user operation per second

The post Over 80% of 135 Ethereum L2s record below 1 user operation per second  appeared on BitcoinEthereumNews.com. Ethereum’s L2s are not doing too well. Data
Share
BitcoinEthereumNews2026/02/05 03:52